Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020

Background: Timely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients. Aim: We assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20. Methods: Case...

Descripción completa

Detalles Bibliográficos
Autores: Adlhoch, Cornelia, Delgado-Sanz, Concepcion, Carnahan, AnnaSara, Larrauri, Amparo, Popovici, Odette, Bossuyt, Nathalie, Thomas, Isabelle, Kynčl, Jan, Slezák, Pavel, Brytting, Mia, Guiomar, Raquel, Redlberger-Fritz, Monika, Maistre Melillo, Jackie, Melillo, Tanya, van Gageldonk-Lafeber, Arianne B, Marbus, Sierk D, O'Donnell, Joan, Domegan, Lisa, Gomes Dias, Joana, Olsen, Sonja J
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16485
Acceso en línea:http://hdl.handle.net/20.500.12105/16485
Access Level:acceso abierto
Palabra clave:Oseltamivir
Influenza, Human
Humans
Aged
Neuraminidase
Hospital Mortality
Antiviral Agents
Enzyme Inhibitors
Guanidines
Zanamivir
Treatment Outcome
id ES_0b4fa37fc741f1f7c4fcc37e99aa874e
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/16485
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020Adlhoch, CorneliaDelgado-Sanz, ConcepcionCarnahan, AnnaSaraLarrauri, AmparoPopovici, OdetteBossuyt, NathalieThomas, IsabelleKynčl, JanSlezák, PavelBrytting, MiaGuiomar, RaquelRedlberger-Fritz, MonikaMaistre Melillo, JackieMelillo, Tanyavan Gageldonk-Lafeber, Arianne BMarbus, Sierk DO'Donnell, JoanDomegan, LisaGomes Dias, JoanaOlsen, Sonja JOseltamivirInfluenza, HumanHumansAgedNeuraminidaseHospital MortalityAntiviral AgentsEnzyme InhibitorsGuanidinesZanamivirTreatment OutcomeBackground: Timely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients. Aim: We assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20. Methods: Case-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated. Results: Of 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)). Conclusion: NAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.European Centre for Disease Prevention and Control (ECDC)20232023-09-2520232023-01-0120232023-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/16485reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/164852026-06-12T12:43:37Z
dc.title.none.fl_str_mv Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
title Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
spellingShingle Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
Adlhoch, Cornelia
Oseltamivir
Influenza, Human
Humans
Aged
Neuraminidase
Hospital Mortality
Antiviral Agents
Enzyme Inhibitors
Guanidines
Zanamivir
Treatment Outcome
title_short Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
title_full Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
title_fullStr Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
title_full_unstemmed Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
title_sort Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
dc.creator.none.fl_str_mv Adlhoch, Cornelia
Delgado-Sanz, Concepcion
Carnahan, AnnaSara
Larrauri, Amparo
Popovici, Odette
Bossuyt, Nathalie
Thomas, Isabelle
Kynčl, Jan
Slezák, Pavel
Brytting, Mia
Guiomar, Raquel
Redlberger-Fritz, Monika
Maistre Melillo, Jackie
Melillo, Tanya
van Gageldonk-Lafeber, Arianne B
Marbus, Sierk D
O'Donnell, Joan
Domegan, Lisa
Gomes Dias, Joana
Olsen, Sonja J
author Adlhoch, Cornelia
author_facet Adlhoch, Cornelia
Delgado-Sanz, Concepcion
Carnahan, AnnaSara
Larrauri, Amparo
Popovici, Odette
Bossuyt, Nathalie
Thomas, Isabelle
Kynčl, Jan
Slezák, Pavel
Brytting, Mia
Guiomar, Raquel
Redlberger-Fritz, Monika
Maistre Melillo, Jackie
Melillo, Tanya
van Gageldonk-Lafeber, Arianne B
Marbus, Sierk D
O'Donnell, Joan
Domegan, Lisa
Gomes Dias, Joana
Olsen, Sonja J
author_role author
author2 Delgado-Sanz, Concepcion
Carnahan, AnnaSara
Larrauri, Amparo
Popovici, Odette
Bossuyt, Nathalie
Thomas, Isabelle
Kynčl, Jan
Slezák, Pavel
Brytting, Mia
Guiomar, Raquel
Redlberger-Fritz, Monika
Maistre Melillo, Jackie
Melillo, Tanya
van Gageldonk-Lafeber, Arianne B
Marbus, Sierk D
O'Donnell, Joan
Domegan, Lisa
Gomes Dias, Joana
Olsen, Sonja J
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Oseltamivir
Influenza, Human
Humans
Aged
Neuraminidase
Hospital Mortality
Antiviral Agents
Enzyme Inhibitors
Guanidines
Zanamivir
Treatment Outcome
topic Oseltamivir
Influenza, Human
Humans
Aged
Neuraminidase
Hospital Mortality
Antiviral Agents
Enzyme Inhibitors
Guanidines
Zanamivir
Treatment Outcome
description Background: Timely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients. Aim: We assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20. Methods: Case-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated. Results: Of 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)). Conclusion: NAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-09-25
2023
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/16485
url http://hdl.handle.net/20.500.12105/16485
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv European Centre for Disease Prevention and Control (ECDC)
publisher.none.fl_str_mv European Centre for Disease Prevention and Control (ECDC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403213479804928
score 15.81155

Similares en LA Referencia